石四药集团(02005.HK)首季归母净利润劲升56.5%至3.03亿港元
格隆汇4月19日丨石四药集团(02005.HK)公布截至2022年3月31日止3个月未经审核经营业绩。
集团截至2022年3月31日止3个月的未经审核营业额较2021年同期增加40.8%至约17.33亿港元(2021年同期:约12.31亿港元)。集团截至2022年3月31日止3个月的未经审核毛利约10.19亿港元(2021年同期:约7.87亿港元),较2021年同期增加29.5%。集团截至2022年3月31日止3个月的未经审核毛利率约为58.8%,较2021年同期下降5.2个百分点,主要原因是原料药所占集团未经审核营业额的比例有所提升,而原料药的毛利率低于药物制剂。
截至2022年3月31日止3个月,集团的未经审核公司股东应占溢利较2021年同期增加56.5%至约3.03亿港元(2021年同期:约1.94亿港元),主要原因是(i)比较2021年同期,原料药的未经审核营业额大幅增加267.1%,当中咖啡因系列产品的未经审核营业额大幅增加超过7倍,对集团未经审核股东应占溢利作出更大贡献;(ii)比较2021年同期,由于原料药的未经审核营业额增加的原因,销售费用率(即未经审核销售费用除以未经审核营业额)有所下降及(iii)截至2022年3月31日止3个月,并无因授出购股权产生的费用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.